ביבליוגרפיה

1. P Abrams, L Cardozo, M Fall, et al.: The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International
Continence Society. Neurourol Urodyn. 21:167-178 2002
2. BT Haylen, D de Ridder, RM Freeman, et al.: An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for
female pelvic floor dysfunction. Neurourol Urodyn. 29:4-20 2010
3. ES Lukacz, EL Whitcomb, JM Lawrence, et al.: Urinary frequency in community-dwelling women: what is normal? Am J Obstet Gynecol. 200:552.e1-552.e7 2009
4. KAO Tikkinen, TM Johnson II, TLJ Tammela, et al.: Nocturia frequency, bother, and quality of life: how often is too often? A Population-Based Study in Finland. Eur Urol. 57:488-
498 2010
5. J-N Cornu, P Abrams, CR Chapple, et al.: A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management—a systematic review and
meta-analysis. Eur Urol. 62:877-890 2012
6. KS Coyne, CC Sexton, CL Thompson, et al.: The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS
(EpiLUTS) study. BJU Int. 104:352-360 2009
7. Y Dooley, K Kenton, Cao G, et al.: Urinary incontinence prevalence: results from the National Health and Nutrition Examination Survey. J Urol. 179:656-661 2008
8. DE Irwin, I Milsom, S Hunskaar, et al.: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of
the EPIC study. Eur Urol. 50:1306-1314 2006
9. WF Stewart, JB Van Rooyen, GW Cundiff, et al.: Prevalence and burden of overactive bladder in the United States. World J Urol. 20:327-336 2003
10. S Heidler, C Mert, C Temml, et al.: The natural history of the overactive bladder syndrome in females: a long-term analysis of a health screening project. Neurourol Urodyn.
30:1437-1441 2011
11. RR Dmochowski, DK Newman: Impact of overactive bladder on women in the United States: results of a national survey. Curr Med Res Opin. 23:65-76 2007
12. MB Chancellor, K Migliaccio-Walle, TJ Bramley, et al.: Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clin Ther. 35:1744-
1751 2013
13. D Kinsey, S Pretorius, L Glover, et al.: The psychological impact of overactive bladder: a systematic review. J Health Psychol. 21:69-81 2016
14. CG Kowalik, JA Cohn, S Delpe, et al.: Painful bladder symptoms related to somatic syndromes in a convenience sample of community women with overactive bladder
symptoms. J Urol. 2018
15. EA Gormley, DJ Lightner, KL Burgio, et al.: Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol
16. C Gratzke, A Bachmann, A Descazeaud, et al.: EAU Guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.
Eur Urol. 67:1099-1109 2015
17. AK Nambiar, R Bosch, F Cruz, et al.: EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol. 73:596-609 2018
18. Campbell's Urology
19. AK Nambiar, GE Lemack, CR Chapple, et al.European Association of Urology: The role of urodynamics in the evaluation of urinary incontinence: the European Association of
Urology Recommendations in 2016. Eur Urol. 71:501-503 2017
20. LA Arya, DL Myers, ND Jackson: Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstet Gynecol. 96:85-89 2000
21. LL Subak, R Wing, DS West, et al.: Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 360:481-490 2009
22. EAU Guidelines
23. Cardwell K, Hughes CM, Ryan C. The association between anticholinergic medication burden and health related outcomes in the ‘oldest old’: a systematic review of the
literature. Drugs Aging. 2015
24. Boustani, M., et al. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health, 2008. 4: 311.
25. Maman, K., et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment
comparison. Eur Urol, 2014
26. Chapple, C.R., et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn, 2014
27. Chapple C, Kaplan S, Mitcheson D, et al. Randomised, double-blind, active-controlled phase III study to assess 12-month safety and efficacy of mirabegron, a β(3)-
adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305
28. Wagg, A., et al. Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients. Drugs Aging, 2015. 32:
103
29. AUA Guidelines
30. HB Goldman, JC Lloyd, KL Noblett, et al.: International Continence Society best practice statement for use of sacral neuromodulation [Internet]. Neurourol Urodyn. 2018
31. Smith CP, Gangitano DA, Munoz A, Salas NA, Boone TB, Aoki KR, et al. Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal
cord injury. Neurochem Int. 2008;52:1068–1075
32. Lawrence GW, Aoki KR, Dolly JO. Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of
transmitters from efferent fibers. J Pharmacol Exp Ther. 2010;334:1080–1086
33. Denys P, Le Normand L, Ghout I, Costa P, Chartier-Kastler E, Grise P, et al. VESITOX study group in France. Efficacy and safety of low doses of onabotulinumtoxinA for the
treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol. 2012;61:520–529.
34. Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome.
Eur Urol. 2010;58:919–926
35. Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botox Detrusor Hyperreflexia Study Team. Botulinum toxin type a is a safe and effective treatment
for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174:196–200